Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

BACKGROUND: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly improved outcomes versus subcutaneous interferon beta-1a (SC IFNB-1a) in relapsing–remitting multiple sclerosis patie...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ther Adv Neurol Disord
Auteurs principaux: Coles, Alasdair J., Arnold, Douglas L., Bass, Ann D., Boster, Aaron L., Compston, D. Alastair S., Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H., Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C., Selmaj, Krzysztof W.
Format: Artigo
Langue:Inglês
Publié: SAGE Publications 2021
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8072102/
https://ncbi.nlm.nih.gov/pubmed/34035833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420982134
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires